Browse by category

The first participants have been dosed in Ascletis Pharma’s US 13-week Phase II study with ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist for the treatment of type 2 diabetes mellitus. Topline data from the Phase II study are expected in the third quarter of 2026. Ascletis recently completed a 13-week Phase II study evaluating ASC30 for the treatment of obesity in 125 participants with obesity or overweight with at least one weight-related comorbidity at multip

Ascletis Pharma has completed enrolment in its US 13-week Phase IIa study evaluating ASC30, a small molecule oral GLP-1 receptor (GLP-1R)...